TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Postural Assessment Scale for Stroke (PASS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of temporal artery temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnetic Resonance Imaging (MRI)-Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Atrial Pacing Capture Threshold Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular Pacing Capture Threshold Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participant Count of Acceptable Trial Mask Performance - Objective
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trial Mask Seal Performance - Subjective
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Trial Mask Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dose limiting toxicity (DLT) rate
Endpoint domain: Adverse events/effects
Primary endpoint: tumor burden assessment by biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall clinical benefit rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FGF2 methylation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Atrial Fibrillation (AF) after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Variation of Dermatology Life Quality Index (DLQI) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants who use condoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who undergo HIV or sexually transmitted infection (STI) testing
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who have pre-exposure prophylaxis (PrEP) interest
Endpoint domain: Adverse events/effects
Primary endpoint: Patients' experience with the different phases of MTC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Association of selected biometric outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Absence of Pneumothoraces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Who Met the Study-defined Composite Safety Endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of HIV-1 Gag-specific CD8+ T-cells by Intracellular Staining for IFN-gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma HIV-1 RNA by SCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of patients with clinically actionable findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-T of telmisartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Upper Body Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Upper Body Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Arm Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: changes in pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: immune activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Concentration of Ivacaftor and Its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PVC frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Virologic Rebound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dental Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Microbiologic findings of piercing samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of Participants With Undetectable Cell-associated HIV-1 DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiorespiratory Fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Yale-Brown Obsessive Compulsive Scale (YBOCS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of people recruited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Long term weight loss maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Controlled Oral Word Association test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Subjects With Complication After Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Speech Distortion Phonemes over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quantitative Tongue Gestures over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of app on CBT-I
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cow's Milk-related Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in plasma calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in osteocalcin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ICU Mortality
Endpoint domain: Mortality/survival
Primary endpoint: clinical cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: sustained clinical cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: global cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Comfort change assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity and specificity of infrared imaging for skin cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Histologic classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: rate of testicular self-exam
Endpoint domain: Life impact
Endpoint subdomain: Health behavior
Primary endpoint: Eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum acid output during pentagastrin stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Diffusion Capacity for Carbon Monoxide (DLco)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bladder tumor proliferation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum A-Protein level class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady State Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjects' Satisfaction of Navina Smart
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subjects' Perception of Navina Smart
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjects' Compliance of Navina Smart
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in serum LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Annualized Height Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of mechanical ventilation support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Premature Infant Pain Profile (PIPP) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Complete Response (CR) or Complete Response Unconfirmed (CRu)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Oral Glucose Tolerance Test (OGTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in stool consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ERK phosphorylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of GS-4774
Endpoint domain: Adverse events/effects
Primary endpoint: Mucoadhesive liquid retention in the oropharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of IL-8 and TNFa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients experiencing hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Prolongation of the QT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: dead space ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: staining potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in the number of urinary leakages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean percentage change in Eczema Area Severity Index (EASI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Willingness to vaccinate child
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pancreatic leak/fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Concordance between initial medical diagnosis and final diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction With Facial Appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of exclusive breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnostic performance (AUC: area of under ROC curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of absolute and relative adrenal insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cumulative requirements of vasoactive drugs during surgery and in the intensive care unit (ICU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Nemolizumab Serum Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Serum Concentration (Cmax) of Nemolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triglycerides (TGs) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in Parkinson disease motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: change in kinematic parameters of the gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in clinical activity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse prevention measured by YMRS and HAMD-21 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-activity data
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Global Assessment of Functioning - change from baseline
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in LS BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Remifentanil EC50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle thickness of the quadriceps femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: accuracy of 3-dimensional measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and proportion of treatment responders per SLE Responder Index (SRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-transfusion reactions
Endpoint domain: Adverse events/effects
Primary endpoint: augmentation of hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: augmentation of hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Circadian Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Symptoms of vulvovaginal atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Forearm Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Verb Structures Per Utterance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serological efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients with ACR 20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion rate for each serotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titer (GMT) of virus neutralizing antibodies for each serotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of BCCs With Complete and at Least Partial Clinical Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With at Least Partial Clinical Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: implant success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Presence of contact allergy
Endpoint domain: Adverse events/effects
Primary endpoint: Mother's total and exclusive breastfeeding rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence density of symptomatic dengue cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in the Walk Index for Spinal Cord Injury, WISCI II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of metastatic relapse
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of ExAblate Transcranial MRgFUS treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average mean glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Variability in glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants achieving sustained virologic response (SVR) 12 weeks after the end of all study therapy (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants experiencing an adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants withdrawing from study therapy due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pre-methacholine lung attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of recurrence of bacterial vaginosis
Endpoint domain: Adverse events/effects
Primary endpoint: response to OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glabellar Line Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of hours spent gaming or online gambling
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Rate of second randomization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hematologic response (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall Colon-cleansing Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Social Anxiety Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Efficacy of DXM-bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of serology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment Success at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean AAdSS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Blood Pressure (Systolic and Diastolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: soft tissue complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Baseline venous blood draw
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: survival at hospital admission
Endpoint domain: Mortality/survival
Primary endpoint: 21 Item Hamilton Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Global Impression Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Brief Psychiatric Rating Scale at 12 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neck Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency-volume chart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dynamic balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of paracetamol and ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-Emergent Adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with changes from baseline in safety parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Peak plasma Concentration measurements (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent and intensity of disease in bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to detect selective lung isolation states
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of bedside abdominal US
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Peripheral Blood Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in Number of Transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-hematologic Toxicity Profile (Grade 2 and Above)
Endpoint domain: Adverse events/effects
Primary endpoint: Stone-free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of gonadotrophins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Oocyte retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Safety of long-term lixivaptan use
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Any new stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Needs of type 1 diabetic patients in therapeutic education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Implementation success of Integrated Nutrition Pathway for Acute Care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mothers' depression symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Infant birth outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of major bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of AEDs-induced cADRs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in height standard deviation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response 12 Weeks Post-Treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response 24 Weeks Post-Treatment (SVR24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes